VIDEO: State of the pipeline, drug updates in atopic dermatitis

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

Lio highlighted the four AD biologics: dupilumab, lebrikizumab, tralokinumab and nemolizumab, each of which had new data presented at the meeting. He also highlighted upadacitinib and abrocitinib, the oral Janus kinase inhibitors for AD.

“Being able to really sit down with colleagues and figure out how are we going to use these things when they finally do come out, or if they do come out. But it sure seems likely that we're going to have even more tools in our toolbox very shortly,” Lio, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, said.